mTOR inhibitors, such as sirolimus and everolimus, have been demonstrated effective in the treatment for several TSC-related lesions, including subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas (AMLs), and pulmonary lymphangioleiomyomatosis (LAM) (Curatolo et al., 2016). This evidence concerns the gene MTOR and tuberous sclerosis.